Bain Capital Life Sciences Investors as of March 31, 2025
Portfolio Holdings for Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors holds 24 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 32.5 | $219M | 11M | 20.47 | |
| Nuvalent Inc-a (NUVL) | 15.2 | $103M | 1.4M | 70.92 | |
| Pharvaris N V (PHVS) | 7.7 | $52M | 3.3M | 15.70 | |
| Disc Medicine (IRON) | 7.2 | $49M | 984k | 49.64 | |
| Dianthus Therapeutics (DNTH) | 7.2 | $49M | 2.7M | 18.14 | |
| Savara (SVRA) | 7.2 | $49M | 18M | 2.77 | |
| Solid Biosciences Com New (SLDB) | 4.3 | $29M | 7.9M | 3.70 | |
| Olema Pharmaceuticals (OLMA) | 3.8 | $26M | 6.8M | 3.76 | |
| Rapid Micro Biosystems Class A Com (RPID) | 3.3 | $22M | 8.4M | 2.64 | |
| Cidara Therapeutics Com New (CDTX) | 2.2 | $15M | 703k | 21.54 | |
| Upstream Bio (UPB) | 2.1 | $14M | 2.3M | 6.12 | |
| Annexon (ANNX) | 1.5 | $10M | 5.2M | 1.93 | |
| Atea Pharmaceuticals (AVIR) | 1.1 | $7.4M | 2.5M | 2.99 | |
| Kyverna Therapeutics (KYTX) | 1.0 | $6.5M | 3.4M | 1.93 | |
| X4 Pharmaceuticals | 0.6 | $4.0M | 17M | 0.24 | |
| Cabaletta Bio (CABA) | 0.6 | $3.8M | 2.8M | 1.39 | |
| Tango Therapeutics (TNGX) | 0.5 | $3.7M | 2.7M | 1.37 | |
| Xilio Therapeutics (XLO) | 0.5 | $3.3M | 4.6M | 0.72 | |
| Mersana Therapeutics | 0.4 | $3.0M | 8.7M | 0.34 | |
| Century Therapeutics (IPSC) | 0.4 | $2.6M | 5.4M | 0.48 | |
| C4 Therapeutics Com Stk (CCCC) | 0.3 | $1.8M | 1.1M | 1.60 | |
| Adagio Therapeutics (IVVD) | 0.2 | $1.1M | 1.8M | 0.61 | |
| Nautilus Biotechnology (NAUT) | 0.1 | $923k | 1.1M | 0.86 | |
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.1 | $899k | 100k | 8.99 |
